Compare Amgen, Inc. (AMGN) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs HSBC Holdings plc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while HSBC Holdings plc trades at $98.41 (market cap $333.00B). The key difference: HSBC Holdings plc is the larger of the two by market cap, and HSBC Holdings plc pays the higher dividend (3.78%). Which is the better fit depends on your goals.
| AMGN | HSBC | |
|---|---|---|
Market Cap | $196.12B | $333.00B |
Sector | Health | Technology |
52-Week High | $388.16 | $99.09 |
52-Week Low | $271.18 | $61.30 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
HSBC trades at $99.09, up 1.09% today and near its 52-week high of $99.47. The stock shows bullish technical signals with consistent earnings beats in recent quarters. Recent news highlights strategic moves, including a potential Turkey business sale and AI expansion with Google Cloud. Revenue is stable at $71.02B for 2025, with a net income margin of 30.81% and a P/E ratio of 16.38.
Outlook is cautiously optimistic, supported by earnings momentum and restructuring efforts. Risks include regulatory penalties and global economic sensitivity. Analysts are mixed, with 38.1% recommending buy. The dividend of $0.50 per share adds income appeal, but investors should monitor execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
